Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark

BMC Public Health

Volumn 12, Issue 1, 2012, Pages

  Olsen, Jens ^a   Jørgensen, Tine Rikke ^b   Kofoed, Kristian ^c   Larsen, Helle Kiellberg ^c  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Sanofi Pasteur MSD ApS   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

Author keywords

Anogenital; Cancer; Cost; HPV; Incidence

Indexed keywords

ADOLESCENT; ADULT; AGED; ANUS TUMOR; ARTICLE; CROSS-SECTIONAL STUDY; DENMARK; ECONOMICS; FEMALE; HOSPITAL COST; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PENIS TUMOR; REGISTER; STATISTICS; VAGINA TUMOR; VULVA TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANUS NEOPLASMS; CROSS-SECTIONAL STUDIES; DENMARK; FEMALE; HOSPITAL COSTS; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PENILE NEOPLASMS; REGISTRIES; VAGINAL NEOPLASMS; VULVAR NEOPLASMS; YOUNG ADULT;

MLCS; MLOWN;

EID: 84870984530     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-12-1082     Document Type: Article

References (23)

1. Chapter 2: The burden of HPV-related cancers. Parkin DM, Bray F, Vaccine 2006 24 Suppl 3 3-11-S3/25
2. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Munoz N, Schiffman M, Bosch FX, Vaccine 2008 26 Suppl 10 17 K28 18847554
3. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Hoots BE, Palefsky JM, Pimenta JM, Smith JS, Int J Cancer 2009 124 2375 2383 10.1002/ijc.24215 19189402
4. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL, Prev Med 2011 53 Suppl 1 12 S21 21962466
5. Human papillomavirus prevalence and type distribution in penile carcinoma. Miralles-Guri C, Bruni L, Cubilla AL, Castellsague X, Bosch FX, de Sanjose S, J Clin Pathol 2009 62 870 878 10.1136/jcp.2008.063149 19706632
6. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. De VH, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S, Int J Cancer 2009 124 1626 1636 10.1002/ijc.24116 19115209
7. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, et al. Cancer Prev Res (Phila) 2009 2 868 878 10.1158/1940-6207.CAPR-09-0031
8. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI, N Engl J Med 2011 365 1576 1585 10.1056/NEJMoa1010971 22029979
9. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D, N Engl J Med 2011 364 401 411 10.1056/NEJMoa0909537 21288094
10. Beyond cervical cancer: burden of other HPV-related cancers among men and women. Chaturvedi AK, J Adolesc Health 2010 46 20 S26 20307840
11. National Board of Health [Sundhedsstyrelsen], The Danish Cancer Register [Cancerregisteret 2009] Copenhagen 2009
12. Human papillomavirus: science and technologies for the elimination of cervical cancer. Bosch FX, Expert Opin Pharmacother 2011 12 2189 2204 10.1517/14656566.2011.596527 21756205
13. Reducing HPV-associated Cancer Globally. Douglas LR, Schiller JT, Cancer Prev Res 2012 5 18 23 10.1158/1940-6207.CAPR-11-0542
14. Ministry of Health and Prevention, National Board of Health [Ministeriet for Sundhed og Forebyggelse, Sundhedsstyrelsen], Charges 2008-Instructions [Takstsystem 2008-Vejledning] Copenhagen 2008
15. Analyzing cost. Glick HA, Doshi JA, Sonnad SS, Polsky D, Economic Evaluation in Clinical Trials Oxford: Oxford University Press 2007
16. Predicting the cost of illness: a comparison of alternative models applied to stroke. Lipscomb J, Ancukiewicz M, Parmigiani G, Hasselblad V, Samsa G, Matchar DB, Med Decis Making 1998 18 39 S56 10.1177/0272989X9801800207 9566466 (Pubitemid 28175942)
17. Modeling risk using generalized linear models. Blough DK, Madden CW, Hornbrook MC, J Health Econ 1999 18 153 171 10.1016/S0167-6296(98)00032-0 10346351 (Pubitemid 29052479)
18. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Olsen J, Jepsen MR, Int J Technol Assess Health Care 2010 26 183 191 10.1017/S0266462310000085 20392322
19. Economic burden of HPV-related cancers in France. Borget I, Abramowitz L, Mathevet P, Vaccine 2011 29 5245 5249 10.1016/j.vaccine.2011.05.018 21616117
20. Economic burden of anal cancer management in France. Abramowitz L, Remy V, Vainchtock A, Rev Epidemiol Sante Publique 2010 58 331 338 10.1016/j.respe.2010.06.165 20869182
21. The economic burden of noncervical human papillomavirus disease in the United States. Hu D, Goldie S, Am J Obstet Gynecol 2008 198 500 507 18455524
22. Prevalence and type distribution of human papillomavirus infection in women from North Sardinia, Italy. Piana A, Sotgiu G, Castiglia P, Pischedda S, Cocuzza C, Capobianco G, et al. BMC Public Health 2011 11 785 10.1186/1471-2458-11-785 21989375
23. Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Rousseau MC, Villa LL, Costa MC, Abrahamowicz M, Rohan TE, Franco E, Sex Transm Dis 2003 30 581 587 10.1097/00007435-200307000-00010 12838088 (Pubitemid 36828984)